Physician profile
Blake Badgett
NPI 1376636084
$7,151.08
in general payments reported to CMS, 2019-2025
31 companies · $2,713 in 2025
The $2,713 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $265 · 2021: $277 · 2022: $440 · 2023: $683 · 2024: $2,626 · 2025: $2,713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,848 · Food and Beverage: $1,984 · Travel and Lodging: $101 · Education: $88.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,847.50 |
| Food and Beverage | $1,983.63 |
| Travel and Lodging | $101.00 |
| Education | $88.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $4,115.19 | 2024-2025 | Voquezna |
| Abbvie INC. | $566.10 | 2023-2025 | Vraylar |
| Astrazeneca Pharmaceuticals Lp | $517.52 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $419.60 | 2019-2025 | Belsomra, Steglatro, Verquvo |
| Pfizer INC. | $214.70 | 2019-2025 | |
| Novo Nordisk INC | $173.92 | 2020-2024 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $132.56 | 2022-2025 | |
| Glaxosmithkline, LLC. | $109.17 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Corcept Therapeutics | $98.40 | 2023-2025 | Korlym |
| Eisai INC. | $73.53 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $67.59 | 2023 | Quviviq |
| Amgen INC. | $63.75 | 2019-2022 | |
| Radius Health, INC. | $60.13 | 2023-2024 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.72 | 2019-2024 | |
| Lilly USA, LLC | $54.67 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $45.97 | 2020-2022 | |
| Adlon Therapeutics L.P. | $43.46 | 2020-2021 | |
| Edwards Lifesciences Corporation | $37.43 | 2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $36.90 | 2022 | |
| Gilead Sciences, INC. | $32.09 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $31.34 | 2021-2023 | Qelbree |
| Janssen Pharmaceuticals, INC | $31.22 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $27.03 | 2022 | |
| Allergan, INC. | $26.80 | 2020 | |
| Organon LLC | $22.37 | 2021 | |
| Sumitomo Pharma America, INC. | $20.49 | 2023 | Gemtesa |
| Dexcom, INC. | $16.00 | 2023 | Dexcom G6 Transmitter |
| Sun Pharmaceutical Industries INC. | $15.33 | 2020 | |
| Ironshore Pharmaceuticals INC. | $13.60 | 2019 | |
| Exeltis, USA INC. | $13.10 | 2024 | |
| Acadia Pharmaceuticals INC | $12.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Badgett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.